ArticleVaccine2012
Short-lived immunity against pertussis, age-specific routes of transmission, and the utility of a teenage booster vaccine.
Article in Vaccine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- The effectiveness and safety of pertussis booster vaccination for adolescents and adults: A systematic review and meta-analysis.Medicine · 2019Pooled it
- Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.Human vaccines & immunotherapeutics · 2018Trial
- Effectiveness and impact of the 2-component acellular pertussis vaccine as a preschool booster in Finland - A register-based study.PLOS global public health · 2026Article
- Predictors of maternal pertussis vaccination acceptance among pregnant women in Norway.Human vaccines & immunotherapeutics · 2024Article
- Pertussis vaccines, epidemiology and evolution.Nature reviews. Microbiology · 2024Review
- Evolution of Bordetella pertussis in the acellular vaccine era in Norway, 1996 to 2019.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Structural basis for antibody binding to adenylate cyclase toxin reveals RTX linkers as neutralization-sensitive epitopes.PLoS pathogens · 2021Article
- Article
- Article
- Infection-acquired versus vaccine-acquired immunity in an SIRWS model.Infectious Disease Modelling · 2018Article
- Risk factors for pertussis in adults and teenagers in England.Epidemiology and infection · 2017Article
- Systematic review and meta-analysis of pertussis epidemiology in Latin America and the Caribbean: 1980-2015.Revista panamericana de salud publica = Pan American journal of public health · 2017Article
- Comparative Epidemiologic Characteristics of Pertussis in 10 Central and Eastern European Countries, 2000-2013.PloS one · 2016Article
- Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.Journal of medicinal chemistry · 2015Article
- Understanding Trends in Pertussis Incidence: An Agent-Based Model Approach.American journal of public health · 2015Article
- Characteristics of Hospitalized Cases of Pertussis in Catalonia and Navarra, Two Regions in the North of Spain.PloS one · 2015Article
- Serotype-Specific Transmission and Waning Immunity of Endemic Foot-and-Mouth Disease Virus in Cameroon.PloS one · 2015Article
- Different effects of whole-cell and acellular vaccines on Bordetella transmission.The Journal of infectious diseases · 2014Article
- Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin.Epidemiology and infection · 2014Review
- Licensed pertussis vaccines in the United States. History and current state.Human vaccines & immunotherapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPertussis incidence has been increasing for the past two decades in Norway, as in much of the highly vaccinated world. The greatest increase is in teenagers, although the most severe cases occur in infants. A teenage booster is recommended globally, largely with the aim of reducing infant incidence. However few countries have implemented the booster, and almost no data have been published on its utility in preventing infant cases. We aim to assess the duration of vaccine-induced immunity, and the possibility for a teenage-booster vaccine to protect infants in Norway. METHODS AND
findingsWe used a unique data set that merged case reports with a national vaccine registry from Norway, 1996-2010, to assess age- and cohort-specific hazards of infection. We also developed and implemented a likelihood-based method for estimating the duration of immunity, taking into account age-contact data relevant for pertussis transmission. The risk of infection in thirteen-year olds increased nearly four-fold, however the hazard in infants did not significantly change. The seasonality of cases in pre-school-aged children differed from that of school-aged children. The introduction of a childhood booster vaccine provided indirect protection for unvaccinated members of the cohort, but little protection to neighboring cohorts. Additionally, we found evidence for increasingly rapid infection after three doses of vaccine, potentially caused by significant and heterogeneous loss of immunity. An estimated 15% of vaccinated individuals lost their immunity within five years after vaccination.
conclusionsImmunity induced by the acellular pertussis vaccine prevents both disease and transmission, but is short-lived and heterogeneous. The age-mixing patterns lead to little contact between teenagers and infants. Therefore, while a teenage booster vaccine campaign would likely provide strong protection for cohorts of teenagers, it would provide little protection for infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.